Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005)

David S. Hong; Maria E. Cabanillas; Jennifer Jane Wheler; Aung Naing; Apostolia M. Tsimberidou; Lei Ye; Steven G. Waguespack; Mike Hernandez; Adel K. El Naggar; Savita Bidyasar; John Wright; Steven I. Sherman; Razelle Kurzrock; Naifa L. Busaidy

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005)

David S. Hong, Maria E. Cabanillas, Jennifer Jane Wheler, Aung Naing, Apostolia M. Tsimberidou, Lei Ye, Steven G. Waguespack, Mike Hernandez, Adel K. El Naggar, Savita Bidyasar, John Wright, Steven I. Sherman, Razelle Kurzrock, Naifa L. Busaidy

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	2286
Number of pages	1
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	96
Issue number	7
State	Published - Jul 1 2011

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

Cite this

Hong, D. S., Cabanillas, M. E., Wheler, J. J., Naing, A., Tsimberidou, A. M., Ye, L., Waguespack, S. G., Hernandez, M., El Naggar, A. K., Bidyasar, S., Wright, J., Sherman, S. I., Kurzrock, R., & Busaidy, N. L. (2011). Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism, 96(7), 2286.

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). / Hong, David S.; Cabanillas, Maria E.; Wheler, Jennifer Jane et al.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 96, No. 7, 01.07.2011, p. 2286.

Research output: Contribution to journal › Comment/debate › peer-review

Hong, DS , Cabanillas, ME, Wheler, JJ, Naing, A , Tsimberidou, AM, Ye, L, Waguespack, SG , Hernandez, M , El Naggar, AK, Bidyasar, S, Wright, J, Sherman, SI, Kurzrock, R & Busaidy, NL 2011, 'Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005)', Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp. 2286.

Hong DS , Cabanillas ME, Wheler JJ, Naing A , Tsimberidou AM, Ye L et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 2011 Jul 1;96(7):2286.

Hong, David S. ; Cabanillas, Maria E. ; Wheler, Jennifer Jane et al. / Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). In: Journal of Clinical Endocrinology and Metabolism. 2011 ; Vol. 96, No. 7. pp. 2286.

@article{4eaea82a858e418eadb0ed99e3eb0743,

title = "Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005)",

author = "Hong, {David S.} and Cabanillas, {Maria E.} and Wheler, {Jennifer Jane} and Aung Naing and Tsimberidou, {Apostolia M.} and Lei Ye and Waguespack, {Steven G.} and Mike Hernandez and {El Naggar}, {Adel K.} and Savita Bidyasar and John Wright and Sherman, {Steven I.} and Razelle Kurzrock and Busaidy, {Naifa L.}",

year = "2011",

month = jul,

day = "1",

language = "English (US)",

volume = "96",

pages = "2286",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "7",

}

TY - JOUR

T1 - Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005)

AU - Hong, David S.

AU - Cabanillas, Maria E.

AU - Wheler, Jennifer Jane

AU - Naing, Aung

AU - Tsimberidou, Apostolia M.

AU - Ye, Lei

AU - Waguespack, Steven G.

AU - Hernandez, Mike

AU - El Naggar, Adel K.

AU - Bidyasar, Savita

AU - Wright, John

AU - Sherman, Steven I.

AU - Kurzrock, Razelle

AU - Busaidy, Naifa L.

PY - 2011/7/1

Y1 - 2011/7/1

UR - http://www.scopus.com/inward/record.url?scp=79960102479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960102479&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:79960102479

SN - 0021-972X

VL - 96

SP - 2286

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 7

ER -

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005)

ASJC Scopus subject areas

Other files and links

Cite this